Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
Phase I Study of the Aurora Kinase a Inhibitor MLN8237 in Combination With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies
Status: Enrolling
Updated:  4/10/2018
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
Phase I Study of the Aurora Kinase a Inhibitor MLN8237 in Combination With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies
Status: Enrolling
Updated: 4/10/2018
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
Click here to add this to my saved trials
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
Phase I Study of the Aurora Kinase a Inhibitor MLN8237 in Combination With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies
Status: Enrolling
Updated:  4/10/2018
University of Pittsburgh Cancer Institute (UPCI)
mi
from
Pittsburgh, PA
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
Phase I Study of the Aurora Kinase a Inhibitor MLN8237 in Combination With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies
Status: Enrolling
Updated: 4/10/2018
University of Pittsburgh Cancer Institute (UPCI)
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
Phase I Study of the Aurora Kinase a Inhibitor MLN8237 in Combination With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies
Status: Enrolling
Updated:  4/10/2018
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
Phase I Study of the Aurora Kinase a Inhibitor MLN8237 in Combination With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies
Status: Enrolling
Updated: 4/10/2018
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections
A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared With Ertapenem in Complicated Urinary Tract Infections
Status: Enrolling
Updated:  4/10/2018
Clinical Research Facility
mi
from
Fullerton, CA
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections
A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared With Ertapenem in Complicated Urinary Tract Infections
Status: Enrolling
Updated: 4/10/2018
Clinical Research Facility
mi
from
Fullerton, CA
Click here to add this to my saved trials
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections
A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared With Ertapenem in Complicated Urinary Tract Infections
Status: Enrolling
Updated:  4/10/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections
A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared With Ertapenem in Complicated Urinary Tract Infections
Status: Enrolling
Updated: 4/10/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections
A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared With Ertapenem in Complicated Urinary Tract Infections
Status: Enrolling
Updated:  4/10/2018
Clinical Research Facility
mi
from
Torrance, CA
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections
A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared With Ertapenem in Complicated Urinary Tract Infections
Status: Enrolling
Updated: 4/10/2018
Clinical Research Facility
mi
from
Torrance, CA
Click here to add this to my saved trials
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections
A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared With Ertapenem in Complicated Urinary Tract Infections
Status: Enrolling
Updated:  4/10/2018
Clinical Research Facility
mi
from
Coral Gables, FL
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections
A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared With Ertapenem in Complicated Urinary Tract Infections
Status: Enrolling
Updated: 4/10/2018
Clinical Research Facility
mi
from
Coral Gables, FL
Click here to add this to my saved trials
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections
A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared With Ertapenem in Complicated Urinary Tract Infections
Status: Enrolling
Updated:  4/10/2018
Clinical Research Facility
mi
from
Doral, FL
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections
A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared With Ertapenem in Complicated Urinary Tract Infections
Status: Enrolling
Updated: 4/10/2018
Clinical Research Facility
mi
from
Doral, FL
Click here to add this to my saved trials
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections
A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared With Ertapenem in Complicated Urinary Tract Infections
Status: Enrolling
Updated:  4/10/2018
Clinical Research Facility
mi
from
Miami, FL
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections
A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared With Ertapenem in Complicated Urinary Tract Infections
Status: Enrolling
Updated: 4/10/2018
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections
A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared With Ertapenem in Complicated Urinary Tract Infections
Status: Enrolling
Updated:  4/10/2018
Clinical Research Facility
mi
from
Saint Louis, MO
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections
A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared With Ertapenem in Complicated Urinary Tract Infections
Status: Enrolling
Updated: 4/10/2018
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections
A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared With Ertapenem in Complicated Urinary Tract Infections
Status: Enrolling
Updated:  4/10/2018
Clinical Research Facility
mi
from
Las Vegas, NV
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections
A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared With Ertapenem in Complicated Urinary Tract Infections
Status: Enrolling
Updated: 4/10/2018
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections
A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared With Ertapenem in Complicated Urinary Tract Infections
Status: Enrolling
Updated:  4/10/2018
Clinical Research Facility
mi
from
Baytown, TX
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections
A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared With Ertapenem in Complicated Urinary Tract Infections
Status: Enrolling
Updated: 4/10/2018
Clinical Research Facility
mi
from
Baytown, TX
Click here to add this to my saved trials
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections
A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared With Ertapenem in Complicated Urinary Tract Infections
Status: Enrolling
Updated:  4/10/2018
509
mi
from
Graz,
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections
A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared With Ertapenem in Complicated Urinary Tract Infections
Status: Enrolling
Updated: 4/10/2018
509
mi
from
Graz,
Click here to add this to my saved trials
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections
A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared With Ertapenem in Complicated Urinary Tract Infections
Status: Enrolling
Updated:  4/10/2018
Clinical Research Facility
mi
from
Columbus, GA
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections
A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared With Ertapenem in Complicated Urinary Tract Infections
Status: Enrolling
Updated: 4/10/2018
Clinical Research Facility
mi
from
Columbus, GA
Click here to add this to my saved trials
CHP 834 Unrelated and Partially Matched Related Donor Peripheral Stem Cell Transportation for T and B Cell Depletion
CHP 834 Unrelated and Partially Matched Related Donor Peripheral Stem Cell Transportation With the CliniMACs Device for T and B Cell Depletion
Status: Enrolling
Updated:  4/11/2018
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
CHP 834 Unrelated and Partially Matched Related Donor Peripheral Stem Cell Transportation for T and B Cell Depletion
CHP 834 Unrelated and Partially Matched Related Donor Peripheral Stem Cell Transportation With the CliniMACs Device for T and B Cell Depletion
Status: Enrolling
Updated: 4/11/2018
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort
Clinical Implementation of Metagenomic Next-Generation Sequencing for Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort
Status: Enrolling
Updated:  4/11/2018
University of California- Davis Medical Center
mi
from
Davis, CA
Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort
Clinical Implementation of Metagenomic Next-Generation Sequencing for Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort
Status: Enrolling
Updated: 4/11/2018
University of California- Davis Medical Center
mi
from
Davis, CA
Click here to add this to my saved trials
Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort
Clinical Implementation of Metagenomic Next-Generation Sequencing for Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort
Status: Enrolling
Updated:  4/11/2018
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort
Clinical Implementation of Metagenomic Next-Generation Sequencing for Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort
Status: Enrolling
Updated: 4/11/2018
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort
Clinical Implementation of Metagenomic Next-Generation Sequencing for Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort
Status: Enrolling
Updated:  4/11/2018
University of California Los Angeles Medical Center
mi
from
Los Angeles, CA
Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort
Clinical Implementation of Metagenomic Next-Generation Sequencing for Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort
Status: Enrolling
Updated: 4/11/2018
University of California Los Angeles Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort
Clinical Implementation of Metagenomic Next-Generation Sequencing for Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort
Status: Enrolling
Updated:  4/11/2018
University of California, San Francisco Medical Center
mi
from
San Francisco, CA
Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort
Clinical Implementation of Metagenomic Next-Generation Sequencing for Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort
Status: Enrolling
Updated: 4/11/2018
University of California, San Francisco Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort
Clinical Implementation of Metagenomic Next-Generation Sequencing for Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort
Status: Enrolling
Updated:  4/11/2018
Children's Hospital Colordao
mi
from
Denver, CO
Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort
Clinical Implementation of Metagenomic Next-Generation Sequencing for Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort
Status: Enrolling
Updated: 4/11/2018
Children's Hospital Colordao
mi
from
Denver, CO
Click here to add this to my saved trials
Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort
Clinical Implementation of Metagenomic Next-Generation Sequencing for Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort
Status: Enrolling
Updated:  4/11/2018
Childrens National Medical Center
mi
from
Washington,
Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort
Clinical Implementation of Metagenomic Next-Generation Sequencing for Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort
Status: Enrolling
Updated: 4/11/2018
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort
Clinical Implementation of Metagenomic Next-Generation Sequencing for Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort
Status: Enrolling
Updated:  4/11/2018
St. Jude Children's Research Hospital
mi
from
Nashville, TN
Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort
Clinical Implementation of Metagenomic Next-Generation Sequencing for Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort
Status: Enrolling
Updated: 4/11/2018
St. Jude Children's Research Hospital
mi
from
Nashville, TN
Click here to add this to my saved trials
Genotypes and Phenotypes in Pediatric SIRS and Sepsis
Genotypes and Phenotypes in Pediatric SIRS and Sepsis (GAPPSS)
Status: Enrolling
Updated:  4/17/2018
Seattle Children's Hospital
mi
from
Seattle, WA
Genotypes and Phenotypes in Pediatric SIRS and Sepsis
Genotypes and Phenotypes in Pediatric SIRS and Sepsis (GAPPSS)
Status: Enrolling
Updated: 4/17/2018
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Clinical Outcomes With Ceftolozane-tazobactam for MDR Pseudomonas Infections
Clinical Outcomes With Ceftolozane-tazobactam in Patients With Multi Drug Resistant (MDR) Pseudomonas Aeruginosa Infections
Status: Enrolling
Updated:  4/17/2018
Temple University, School of Pharmacy
mi
from
Philadelphia, PA
Clinical Outcomes With Ceftolozane-tazobactam for MDR Pseudomonas Infections
Clinical Outcomes With Ceftolozane-tazobactam in Patients With Multi Drug Resistant (MDR) Pseudomonas Aeruginosa Infections
Status: Enrolling
Updated: 4/17/2018
Temple University, School of Pharmacy
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Procalcitonin and Endotoxin Sequential Levels to Optimize the Treatment of Bloodstream Infections
Procalcitonin and Endotoxin Sequential Levels to Optimize the Treatment of Bloodstream Infections
Status: Enrolling
Updated:  4/18/2018
Nebraska Medical Center
mi
from
Omaha, NE
Procalcitonin and Endotoxin Sequential Levels to Optimize the Treatment of Bloodstream Infections
Procalcitonin and Endotoxin Sequential Levels to Optimize the Treatment of Bloodstream Infections
Status: Enrolling
Updated: 4/18/2018
Nebraska Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Pro-calcitonin for Early Detection of Septic Arthritis
Pro-calcitonin for Early Detection of Septic Arthritis
Status: Enrolling
Updated:  4/18/2018
Children's Hospitals and Clinics of Minnesota
mi
from
Minneapolis, MN
Pro-calcitonin for Early Detection of Septic Arthritis
Pro-calcitonin for Early Detection of Septic Arthritis
Status: Enrolling
Updated: 4/18/2018
Children's Hospitals and Clinics of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated:  4/18/2018
San Marcus Research Clinic
mi
from
Miami, FL
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated: 4/18/2018
San Marcus Research Clinic
mi
from
Miami, FL
Click here to add this to my saved trials
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated:  4/18/2018
Infectious Disease Associates of Central Virginia
mi
from
Lynchburg, VA
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated: 4/18/2018
Infectious Disease Associates of Central Virginia
mi
from
Lynchburg, VA
Click here to add this to my saved trials
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated:  4/18/2018
North Alabama Research Center
mi
from
Athens, AL
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated: 4/18/2018
North Alabama Research Center
mi
from
Athens, AL
Click here to add this to my saved trials
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated:  4/18/2018
Lalla-Reddy Medical Corporation
mi
from
Fountain Valley, CA
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated: 4/18/2018
Lalla-Reddy Medical Corporation
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated:  4/18/2018
eStudySite
mi
from
La Mesa, CA
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated: 4/18/2018
eStudySite
mi
from
La Mesa, CA
Click here to add this to my saved trials
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated:  4/18/2018
Clinical Research Atlanta
mi
from
Stockbridge, GA
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated: 4/18/2018
Clinical Research Atlanta
mi
from
Stockbridge, GA
Click here to add this to my saved trials
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated:  4/18/2018
Snake River Research, PLLC
mi
from
Idaho Falls, ID
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated: 4/18/2018
Snake River Research, PLLC
mi
from
Idaho Falls, ID
Click here to add this to my saved trials
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated:  4/18/2018
Henry Ford Health System
mi
from
Detroit, MI
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated: 4/18/2018
Henry Ford Health System
mi
from
Detroit, MI
Click here to add this to my saved trials
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated:  4/18/2018
Mercury St Medical Group, PLLC
mi
from
Butte, MT
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated: 4/18/2018
Mercury St Medical Group, PLLC
mi
from
Butte, MT
Click here to add this to my saved trials
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated:  4/18/2018
Quality Clinical Research, Inc.
mi
from
Omaha, NE
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated: 4/18/2018
Quality Clinical Research, Inc.
mi
from
Omaha, NE
Click here to add this to my saved trials
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated:  4/18/2018
Jersey Shore University Medical Center
mi
from
Neptune, NJ
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated: 4/18/2018
Jersey Shore University Medical Center
mi
from
Neptune, NJ
Click here to add this to my saved trials
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated:  4/18/2018
Univ of Rochester Medical Center
mi
from
Rochester, NY
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated: 4/18/2018
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated:  4/18/2018
Remington Davis Inc.
mi
from
Columbus, OH
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated: 4/18/2018
Remington Davis Inc.
mi
from
Columbus, OH
Click here to add this to my saved trials
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated:  4/18/2018
Baylor Scott & White Research Institute
mi
from
Temple, TX
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated: 4/18/2018
Baylor Scott & White Research Institute
mi
from
Temple, TX
Click here to add this to my saved trials
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated:  4/18/2018
Dr. Hansen Internal Medicine
mi
from
Bountiful, UT
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated: 4/18/2018
Dr. Hansen Internal Medicine
mi
from
Bountiful, UT
Click here to add this to my saved trials
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated:  4/18/2018
Omega Research Consultants, Llc
mi
from
Orlando, FL
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated: 4/18/2018
Omega Research Consultants, Llc
mi
from
Orlando, FL
Click here to add this to my saved trials
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated:  4/18/2018
Emory University Hospital
mi
from
Atlanta, GA
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated: 4/18/2018
Emory University Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated:  4/18/2018
Anne Arundel Health System Research Institute, Inc.
mi
from
Annapolis, MD
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated: 4/18/2018
Anne Arundel Health System Research Institute, Inc.
mi
from
Annapolis, MD
Click here to add this to my saved trials
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated:  4/18/2018
The Mayo Clinic
mi
from
Rochester, MN
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated: 4/18/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated:  4/18/2018
Montefiore Medical Center
mi
from
Bronx, NY
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated: 4/18/2018
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated:  4/18/2018
Regional Infectious Diseases Infusion Center
mi
from
Lima, OH
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated: 4/18/2018
Regional Infectious Diseases Infusion Center
mi
from
Lima, OH
Click here to add this to my saved trials
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated:  4/18/2018
Sundance Clinical Research, LLC
mi
from
Saint Louis, MO
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence
Status: Enrolling
Updated: 4/18/2018
Sundance Clinical Research, LLC
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Blood Culture Improvement Guidelines and Diagnostic Stewardship for Antibiotic Reduction in Critically Ill Children
Blood Culture Improvement Guidelines and Diagnostic Stewardship for Antibiotic Reduction in Critically Ill Children
Status: Enrolling
Updated:  4/18/2018
St. Louis Children's Hospital at Washington University
mi
from
Saint Louis, MO
Blood Culture Improvement Guidelines and Diagnostic Stewardship for Antibiotic Reduction in Critically Ill Children
Blood Culture Improvement Guidelines and Diagnostic Stewardship for Antibiotic Reduction in Critically Ill Children
Status: Enrolling
Updated: 4/18/2018
St. Louis Children's Hospital at Washington University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Blood Culture Improvement Guidelines and Diagnostic Stewardship for Antibiotic Reduction in Critically Ill Children
Blood Culture Improvement Guidelines and Diagnostic Stewardship for Antibiotic Reduction in Critically Ill Children
Status: Enrolling
Updated:  4/18/2018
Rainbow Babies and Children's Hospital
mi
from
Cleveland, OH
Blood Culture Improvement Guidelines and Diagnostic Stewardship for Antibiotic Reduction in Critically Ill Children
Blood Culture Improvement Guidelines and Diagnostic Stewardship for Antibiotic Reduction in Critically Ill Children
Status: Enrolling
Updated: 4/18/2018
Rainbow Babies and Children's Hospital
mi
from
Cleveland, OH
Click here to add this to my saved trials